Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation
W J Heinz1, H Einsele, A Helle-Beyersdorf
1Department of Internal Medicine II, University of Wuerzburg Medical Center, Wuerzburg, Germany.
Summary
Monitoring posaconazole serum levels is crucial for stem cell transplant patients. Achieving concentrations over 500 ng/mL may indicate effective antifungal drug levels, improving patient outcomes.
Area of Science:
- Pharmacology
- Mycology
- Hematology
Background:
- Posaconazole is recommended for fungal infection prophylaxis and invasive aspergillosis treatment post-stem cell transplant.
- Evidence suggests a correlation between posaconazole drug concentration and treatment efficacy.
Purpose of the Study:
- To investigate serum posaconazole levels in allogeneic stem cell recipients.
- To evaluate the predictive value of early posaconazole concentrations for achieving therapeutic levels.
Main Methods:
- Serum samples from 64 allogeneic stem cell recipients (262 samples) were analyzed for posaconazole levels.
- Interindividual variations, including sex, age, and dosing regimens, were assessed.
- The predictive value of initial steady-state concentrations and concentrations at any time point was evaluated.
Main Results:
- Significant interindividual variation in posaconazole serum levels was observed.
- Male patients exhibited higher median concentrations (570 ng/mL) than female patients (426 ng/mL).
- Initial posaconazole concentrations >300 ng/mL or >500 ng/mL predicted higher subsequent levels >500 ng/mL in patients on 400 mg BID dosing.
Conclusions:
- A posaconazole serum concentration >500 ng/mL at any time may predict sufficient drug exposure.
- Early monitoring of posaconazole levels can guide therapy to optimize antifungal prophylaxis and treatment.
- These findings support therapeutic drug monitoring for posaconazole in immunocompromised patients.
